NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

家族性高膽固醇血症 (II型高脂蛋白血症) :市場考察、流行病學、市場預測 (∼2030年)

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)- Market Insight, Epidemiology and Market Forecast -2030

出版商 DelveInsight Business Research LLP 商品編碼 980939
出版日期 按訂單生產 內容資訊 英文 21 Pages
商品交期: 2-10個工作天內
價格
家族性高膽固醇血症 (II型高脂蛋白血症) :市場考察、流行病學、市場預測 (∼2030年) Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)- Market Insight, Epidemiology and Market Forecast -2030
出版日期: 按訂單生產內容資訊: 英文 21 Pages
簡介

主要7個市場的家族性高膽固醇血症(FH)的患病者總數2020年估計3,113,189人。主要7個市場的2020年的發病者總數估計598,635人,預計至2030年增加。

美國的FH的發病者數,2020年估計323,808人。2017年,美國的FH患病人數50∼59歲的年齡層以75,780人最多,其次是60∼69歲的69,683人。

在歐洲5個國家中,2017年法國的FH發病者數成為最大,其次是英國。日本,2020年的FH發病者數為54,452人。

本報告提供美國,歐洲5個國家 (德國,西班牙,義大利,法國,英國) ,及日本等7個主要市場上家族性高膽固醇血症 (II型高脂蛋白血症) 市場相關調查,市場概要,目前治療方法,新藥,各治療方法的市場佔有率,及市場規模預測等,市場成長的推動要素與阻礙,未滿足需求,機會潛在的可能性等相關分析。

目錄

第1章 重要的洞察

第2章 家族性高膽固醇血症 (II型高脂蛋白血症)的市場概要

第3章 摘要整理

第4章 家族性高膽固醇血症 (II型高脂蛋白血症) :疾病的背景和概要

  • 簡介
  • 家族性高膽固醇血症
    • 均質連接性家族性高膽固醇血症(HoFH)
    • 雜合子家族性高膽固醇血症(HeFH)
  • FH原因遺傳基因
    • LDL受體
    • 預約B-100
    • PCSK9
    • LDL受體配接器蛋白質1(LDLRAP1)
  • 症狀
  • FH的臨床性特徵
    • 高LDL-膽固醇血症
    • 青年性冠狀動脈疾病
    • 肌腱及皮膚黃色瘤
    • 角膜環
    • FH的其他危險因素
  • 診斷
    • 遺傳基因篩檢的FH檢測
    • 連鎖篩檢的FH檢測
    • 跟腱X光攝影
    • 兒童FH的診斷
    • 診斷的確立
  • 鑑別診斷

第5章 American Heart Association (AHA) 的家族性高膽固醇血症的診斷指南

第6章 National Institute for Health and Care Excellence (NICE) 的家族性高膽固醇血症的診斷指南

第7章 認證設施

  • 美國
  • 歐洲
  • 日本

第8章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的家族性高膽固醇血症的患病人數
  • 主要7個國家的家族性高膽固醇血症的發病者數

第9章 家族性高膽固醇血症(FH)的流行病學:各國

  • 美國
    • 前提條件與理論性根據
    • 盛行率
    • 患病人數
    • 各年齡分佈
    • 突然變異特異性分佈
  • 歐洲5個國家
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第10章 治療

  • 生活方式的變更
  • 藥理學性治療
    • Statin
    • 膽固醇吸收抑制劑
    • 膽汁酸封鎖劑
    • Juxtapid (Lomitapide)
    • PCSK9抑制劑
  • 脂蛋白血球分離
  • 肝臟移植

第11章 American Heart Association (AHA) 的家族性高膽固醇血症的治療指南

第12章 National Institute for Health and Care Excellence (NICE) 的治療指南

  • FH的管理

第13章 Japan Atherosclerosis Society 及 the Asian Pacific Society of Atherosclerosis and Vascular Diseases 的家族性高膽固醇血症的治療指南

第14章 未滿足需求

第15章 成藥

  • 主要的其他競爭公司
  • Praluent (alirocumab): Sanofi/Regeneron Pharmaceuticals
    • 藥的說明
    • 法規的里程碑
    • 其他開發活動
    • 目前開發平台活動
    • 安全性和有效性
    • 產品簡介
  • Repatha (evolocumab): Amgen
  • Nustendi/Nexlizet (bempedoic acid/ezetimibe): Esperion Therapeutics
  • Juxtapid (Lomitapide): Aegerion Pharmaceutical
  • Nexletol (bempedoic acid/Nilemdo): Esperion Therapeutics
    • 其他開發活動

第16章 新藥

  • 主要的其他競爭公司
  • Evinacumab(REGN1500):Regeneron Pharmaceuticals
    • 藥的說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • 界內栗子矽烷(ALN-PCSSC):諾華
    • 臨床試驗資訊
  • LIB003:LIB Therapeutics
  • Gemcabene: NeuroBo Pharmaceuticals
    • 產品說明
    • 其他發展活動
  • ARO-ANG3:Arrowhead Pharmaceuticals

第17章 家族性高膽固醇血症(FH):主要7個市場分析

  • 主要調查結果
  • 主要7個國家的家族性高膽固醇血症(FH)的市場規模
  • 主要7個國家市場預測
  • 美國的市場規模
    • 家族性高膽固醇血症的整體市場規模
    • 目前治療方法的市場規模
    • 新的治療方法的市場規模
  • 德國的市場規模
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模
  • 日本的市場規模

第18章 病例報告

第19章 市場促進因素

第20章 市場障礙

第21章市場進入 與醫療費償付

第22章 SWOT分析

第23章 附錄

  • 參考文件

第24章 報告的調查手法

第25章 DelveInsight的服務內容

第26章 免責聲明

第27章 關於DelveInsight

目錄
Product Code: DIMI0083

DelveInsight's 'Familial Hypercholesterolemia (FH) - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Familial Hypercholesterolemia (FH), historical and forecasted epidemiology as well as the Familial Hypercholesterolemia (FH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Familial Hypercholesterolemia (FH) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Familial Hypercholesterolemia (FH) market size from 2017 to 2030. The report also covers current Familial Hypercholesterolemia (FH) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Familial Hypercholesterolemia (FH) Disease Understanding and Treatment Algorithm

Familial Hypercholesterolemia (FH) Overview

Familial Hypercholesterolemia (FH) is a genetic and hereditary disorder, which leads to a high level of LDL (bad) cholesterol. The condition begins at birth and can cause heart attacks at an early age.

FH is an autosomal-dominant disorder associated with mutations in the LDL receptor gene resulting in elevated plasma low-density lipoprotein cholesterol levels and premature atherosclerotic cardiovascular disease (ASCVD). FH is significantly under-recognized with as many as 1 in 300 having the heterozygous form and one in a million having the homozygous form of the disease. Patients with FH are characterized by a decreased clearance of LDL from the circulation and an increase in LDL synthesis, with changes in homozygotes being more marked than in heterozygotes, consistent with a gene dosage effect.

Heterozygous FH (HeFH) (mutation in one allele) is related with plasma LDL-C levels >190 mg/dL, whereas homozygous FH (HoFH) (mutation in both alleles) is associated with plasma LDL-C levels >500 mg/dL. As a result, there is a 20-fold increase in the risk of premature coronary heart disease (CHD) in untreated patients compared to control. HeFH patients usually develop CHD, without treatment, before age 55 and 60 for men and women, respectively. HoFH patients, however, develop CHD very early in life and can die before age 20 if untreated.

Familial Hypercholesterolemia (FH) Diagnosis

In general, an estimated 20 million people worldwide have FH. Despite the high prevalence and increased risk of premature ASCVD in untreated patients, less than 1% are diagnosed with FH worldwide.

Family history, physical examination and a lipid profile are essential to establishing a diagnosis of FH. FH should be suspected with fasting LDL-C ≥190 mg/dL in adults and ≥160 mg/dL in children if secondary causes of hypercholesterolemia, such as hypothyroidism, nephritic syndrome, and liver disease are ruled out. The presence of xanthomas, corneal arcus, and xanthelasmas before the age of 60 are highly suggestive of FH, more specifically homozygous FH (HoFH), although sitosterolemia should be ruled out as a cause. Individuals affected by homozygous FH possess two mutant alleles at the LDLR, ApoB, PCSK9, or LDLRAP1 gene loci. Individuals may also be genetically compound heterozygotes but may phenotypically look homozygous with severely elevated LDL-C and physical symptoms. Assessment of family history of high LDL-C and premature coronary heart disease is crucial for HoFH diagnosis.

Familial Hypercholesterolemia (FH) Treatment

Early diagnosis and treatment of FH are vital to reduce the risk of premature atherosclerotic cardiovascular disease and death. The goal of treatment is to reduce LDL-C by 50 % from baseline levels with lifestyle modification, pharmacologic lipid-lowering therapy, and LDL apheresis and in rare cases, liver transplantation. People who get only one copy of the defective gene from their parents may do well with diet changes and statin drugs. Pharmacologic treatment ranges from statin medications to newer agents such as lomitapide, and PCSK9 inhibitors. Combination therapy is frequently required to accomplish goal lipoprotein level reductions and prevent complications.

Familial Hypercholesterolemia (FH) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalent Population of Familial hypercholesterolemia, Diagnosed Prevalent Population of Familial hypercholesterolemia, Age-specific Distribution of Familial Hypercholesterolemia and Mutation-specific Diagnosed Prevalence of Familial Hypercholesterolemia in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.

Key Findings

This section provides glimpse of the Familial Hypercholesterolemia (FH) epidemiology in the 7MM.

  • The total prevalent population of Familial Hypercholesterolemia (FH) in the seven major markets is estimated to be 3,113,189 in 2020. However, total diagnosed prevalent patient population of Familial Hypercholesterolemia (FH) is estimated to be 598,635 in 2020, which is anticipated to increase by 2030 in the seven major markets.
  • The diagnosed prevalence of FH is estimated to be 323,808 in the United States in 2020.
  • The diagnosed prevalent cases of HoFH and HeFH in the United States were 652 and 289,693 in 2017.
  • In the US, in 2017, FH was most prevalent in the age group of 50-59 years, followed by 60-69 years, with 75,780 and 69,683 cases.
  • In the US, the estimated number of mutation-specific cases of FH caused by LDL receptor, APO B, PCSK9, and other rare mutations (SREBP2, STAP1, LDLRAP1 genes) were 251,148, 14,517, 13,065, and 11,613 cases in 2017.
  • In the EU5 Countries, France had the maximum diagnosed prevalent population of Familial Hypercholesterolemia (FH) in 2017, followed by the United Kingdom.
  • Japan accounts for 54,452 cases of diagnosed prevalent population Familial Hypercholesterolemia (FH) in 2020.

Country Wise- Familial Hypercholesterolemia (FH) Epidemiology

The epidemiology segment also provides the Familial Hypercholesterolemia (FH) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Familial Hypercholesterolemia (FH) Drug Chapters

The drug chapter segment of the Familial Hypercholesterolemia (FH) report encloses the detailed analysis of Familial Hypercholesterolemia (FH) marketed drugs and mid and late stage pipeline drugs. It also helps to understand the Familial Hypercholesterolemia (FH) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Familial Hypercholesterolemia (FH) Marketed Drugs

Praluent (alirocumab): Sanofi/ Regeneron Pharmaceuticals

Alirocumab is marketed by brand name Praluent, which is a human monoclonal antibody that binds to proprotein convertase subtilisin kexin type 9 (PCSK9). PCSK9 binds to the low-density lipoprotein receptors (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. LDLR is the primary receptor that clears circulating LDL, therefore the decrease in LDLR levels by PCSK9 results in higher blood levels of LDL-C. By inhibiting the binding of PCSK9 to LDLR, alirocumab increases the number of LDLRs available to clear LDL, thereby lowering LDL-C levels.

Currently, Praluent has completed a phase III clinical developmental trial for treating HoFH patients. This investigation is being done by Regeneron and Sanofi under a global collaboration agreement. The drug is also being investigated in child population for both HoFH and HeFH.

Products detail in the report…

Repatha (evolocumab): Amgen

Evolocumab is a human monoclonal immunoglobulin G2 (IgG2) directed against human proprotein convertase subtilisin kexin 9 (PCSK9). Evolocumab has an approximate molecular weight (MW) of 144 kDa and is produced in genetically engineered mammalian (Chinese hamster ovary) cells.

Evolocumab binds to PCSK9 and inhibits circulating PCSK9 from binding to the low-density lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR degradation and permitting LDLR to recycle back to the liver cell surface. By inhibiting the binding of PCSK9 to LDLR, evolocumab increases the number of LDLRs available to clear LDL from the blood, thereby lowering LDL-C levels.

Products detail in the report…

Nustendi (bempedoic acid / ezetimibe): Esperion Therapeutics

Nustendi is a combination of bempedoic acid and ezetimibe developed by Esperion Therapeutics. Bempedoic acid has been designed as a once-daily, oral therapy that can significantly reduce low-density lipoprotein cholesterol (LDL-C) levels when added to other lipid-lowering therapies in clinical trials of patients with primary hyperlipidemia who need additional LDL-C lowering.

Products detail in the report…

Juxtapid (Lomitapide): Aegerion Pharmaceutical

Juxtapid (AEGR-733) is a novel oral therapeutic agent for hypercholesterolemia. Its mechanism involves inhibition of microsomal triglyceride transfer protein, resulting in a reduction of LDL cholesterol. The drug directly binds and inhibits microsomal triglyceride transfer protein (MTP), which resides in the lumen of the endoplasmic reticulum, thereby preventing the assembly of apo B containing lipoproteins in enterocytes and hepatocytes. This inhibits the synthesis of chylomicrons and VLDL. The inhibition of the synthesis of VLDL leads to reduced levels of plasma LDL-C.

The drug is a microsomal triglyceride transfer protein inhibitor indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce LDL-C, total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with HoFH.

Products detail in the report…

Nexletol (bempedoic acid/ Nilemdo): Esperion Therapeutics

Nexletol is a prescription medicine used along with diet and other lipid-lowering medicines in the treatment of adults with hypercholesterolemia (heterozygous familial and non-familial) and mixed dyslipidemia. Similar to statins, bempedoic acid also reduces high sensitivity C-reactive protein (hsCRP), a key marker of inflammation associated with cardiovascular disease.

Bempedoic acid is an adenosine triphosphate-citrate lyase (ACL) inhibitor that lowers low-density lipoprotein cholesterol (LDL-C) by inhibition of cholesterol synthesis in the liver. ACL is an enzyme upstream of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase in the cholesterol biosynthesis pathway. Bempedoic acid and its active metabolite, ESP15228, require coenzyme A (CoA) activation by very long-chain acyl-CoA synthetase 1 (ACSVL1) to ETC-1002-CoA and ESP15228-CoA, respectively. ACSVL1 is expressed primarily in the liver. Inhibition of ACL by ETC-1002-CoA results in decreased cholesterol synthesis in the liver and lowers LDL-C in blood via upregulation of low-density lipoprotein receptors.

Products detail in the report…

Familial Hypercholesterolemia (FH) Emerging Drugs

Evinacumab (REGN1500): Regeneron Pharmaceuticals

Evinacumab (REGN1500) is being investigated by Regeneron Pharmaceuticals, which is a fully human monoclonal antibody (mAb) to angiopoietin-like protein 3 (ANGPTL3) that acts as an inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL) administered intravenously. It plays a central role in lipoprotein metabolism by binding to ANGPTL3 with high affinity and specificity, and to completely reverse its inhibitory activity on LPL and EL both in vitro and in vivo thereby reducing the serum triglycerides and VLDL-C levels in the patient (Creative Biolabs, n.d.). ANGPTL3 inhibition increases activity of endothelial lipase and, therefore, decreases HDL-C levels.

Products detail in the report…

Inclisiran (ALN-PCSSC): Novartis

Inclisiran by Novartis is a long-acting, synthetic siRNA directed against PCSK9 and it has been shown to significantly decrease hepatic production of PCSK9 and cause a marked reduction in LDL-C levels. Inclisiran is conjugated to triantennary N-acetylgalactosamine carbohydrates administered via subcutaneous injection. These carbohydrates bind to abundant liver-expressed asialoglycoprotein receptors, leading to the uptake of inclisiran specifically into the hepatocytes.

Products detail in the report…

LIB003: LIB Therapeutics

LIB003 is a PCSK9 Inhibitor being developed by LIB Therapeutics, which is administered subcutaneously. The PCSK9 protein is an important regulator of circulating LDL-C levels, through its inhibitory action on recycling of the LDL receptor (LDLR). LDLR on the liver cell surface binds to LDL and the LDLR-LDL complex is then internalized, after which the LDLR is normally recycled back to the cell surface up to 150 times. Secreted PCSK9 binds to the LDLR on the surface of the hepatocyte, leading to the internalization and degradation of the LDLR in the lysosomes, and reducing the number of LDLRs on the cell surface. Inhibition of secreted PCSK9 should therefore increase the number of available LDLRs on the cell surface and increase uptake of LDL-C into the cell. PCSK9 inhibition thus offers a novel therapeutic mechanism for the lowering of LDL-C levels.

Products detail in the report…

Gemcabene: NeuroBo Pharmaceuticals

Gemcabene, a small molecule and is the monocalcium salt of a dialkyl ether dicarboxylic acid [6,6'-oxybis (2,2-dimethylhexanoic acid)] in late-stage clinical development, lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP). It inhibits both cholesterol and fatty acid synthesis as determined by the C-acetate incorporation in hepatocytes. In addition to LDL lowering, gemcabene reduces plasma levels of CRP in patients by 53.5% in monotherapy and by 71% in combination with statins, indicating that this compound may have anti-inflammatory properties.

Products detail in the report…

Familial Hypercholesterolemia (FH) Market Outlook

This section of the report includes the dynamics of market scenario for FH in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

FH is the most common autosomal dominant genetic disease. It is characterized by extremely elevated levels of low-density lipoprotein cholesterol (LDL-C) and a tendency to early-onset atherosclerotic cardiovascular disease. In general, homozygotes manifest the disease at a much earlier age than heterozygotes, and the condition is more severe. It is important to note that if diagnosed, it can be treated with medicines and a healthy lifestyle.

The current market of FH comprises of several treatment options lying in variable classes, such as Statins alone or in combination with Ezetimibe, MTP inhibitors (Juxtapid), PCSK9 inhibitors (Praluent and Repatha), Nexletol/ Nilemdo (bempedoic acid), Nexlizet/ Nustendi (bempedoic acid and ezetimibe) and others (bile-acid-binding resins). In the case of advanced treatment options, Lipoprotein apheresis can also be opted to treat the patients with FH. While in rare and severe cases, patients can also go for liver transplantation.

The pipeline of FH holds potential products by several key players, such as Regeneron Pharmaceuticals (Evinacumab), Novartis (Inclisiran), LIB Therapeutics (LIB003), Arrowhead Pharmaceuticals (ARO-ANG3) and Praluent (Regeneron Pharmaceuticals).

Key Findings

This section includes a glimpse of the Familial Hypercholesterolemia (FH) 7MM market.

  • The market size of FH in the seven major markets is expected to reach up to USD 2,354.8 Million by 2020.
  • The United States accounts for the largest market size of Familial Hypercholesterolemia (FH), in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
  • Among the EU5 countries, France had the highest market size with USD 162.2 Million in 2017, while Spain had the smallest market size of FH with USD 77.5 Million in 2017.
  • The Japan FH market accounts for USD 204.8 Million in 2020.

The United States Market Outlook

This section provides the total Familial Hypercholesterolemia (FH) market size and market size by therapies in the United States.

EU-5 Market Outlook

The total aspregillosis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Familial Hypercholesterolemia (FH) market size and market size by therapies in Japan are provided.

Familial Hypercholesterolemia (FH) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Familial Hypercholesterolemia (FH) market or expected to get launched in the market during the study period 2017-2030. The analysis covers Familial Hypercholesterolemia (FH) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Familial Hypercholesterolemia (FH) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for Familial Hypercholesterolemia (FH) emerging therapies.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Familial Hypercholesterolemia (FH) market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of Familial Hypercholesterolemia (FH), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.
  • Comprehensive insight has been provided into the Familial Hypercholesterolemia (FH) epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Familial Hypercholesterolemia (FH) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of Familial Hypercholesterolemia (FH) market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Familial Hypercholesterolemia (FH) market.

Report Highlights:

  • In the coming years, Familial Hypercholesterolemia (FH) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Familial Hypercholesterolemia (FH) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Report also covers Mutation-specific diagnosed prevalence of FH, including several mutations such as LDL receptor (LDLR) Mutations, Proprotein Convertase Subtilin/Kexin 9 (PCSK9), Apolipoprotein B (Apo B) and Other rare mutations (SREBP2, and STAP1 genes, LDLRAP1 gene).
  • Delveinsight has analysed age-specific epidemiology of FH and segregated the entire FH patient poplation into certain age groups, namely, <18, 18-29, 30-39, 40-49, 50-59, 60-69, 70+. Among these age groups, FH was most prevalent in the age group of 50-59 years, followed by 60¬-69 years
  • Deleveinsight has segregated prevalence of FH on the basis of genetic types, i.e., homozygous familial hypercholesterolemia (HoFH) and heterozygous hypercholesterolemia (HeFH).
  • Currently, the drugs used for the treatment of FH in the US include Statins (Low, Medium and High Intensity) alone or in combination with Ezetimibe, MTP inhibitor (Juxtapid), PCSK9 Inhibitor (Repatha), PCSK9 Inhibitor (Praluent), Nexletol (Bempedoic acid), Nexlizet (Bempedoic acid and Ezetimibe) and Others (Bile acid sequestrants (cholestyramine, colesevelam), Stanol esters, Fibrates, Binders) along with Lipoprotein Apheresis.
  • Expected Launch of potential therapies, Evinacumab/ REGN1500 (Regeneron Pharmaceuticals), LIB003 (LIB Therapeutics), ARO-ANG3 (Arrowhead Pharmaceuticals), Inclisiran (Novartis), and Alirocumab/ Praluent (Regeneron Pharmaceuticals/ Sanofi), may increase the market size in the coming years, assisted by an increase in the diagnosed prevalent population of FH.

Familial Hypercholesterolemia (FH) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Familial Hypercholesterolemia (FH) Pipeline Analysis
  • Familial Hypercholesterolemia (FH) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Familial Hypercholesterolemia (FH) Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Familial Hypercholesterolemia (FH) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Familial Hypercholesterolemia (FH) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Familial Hypercholesterolemia (FH) market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Familial Hypercholesterolemia (FH) total market size as well as market size by therapies across the 7MM during the forecast period (2020-2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Familial Hypercholesterolemia (FH) market size during the forecast period (2020-2030)?
  • At what CAGR, the Familial Hypercholesterolemia (FH) market is expected to grow at the 7MM level during the forecast period (2020-2030)?
  • What would be the Familial Hypercholesterolemia (FH) market outlook across the 7MM during the forecast period (2020-2030)?
  • What would be the Familial Hypercholesterolemia (FH) market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Familial Hypercholesterolemia (FH)?
  • What is the historical Familial Hypercholesterolemia (FH) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Familial Hypercholesterolemia (FH) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Familial Hypercholesterolemia (FH)?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Familial Hypercholesterolemia (FH) during the forecast period (2020-2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the treatment of Familial Hypercholesterolemia (FH) along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Familial Hypercholesterolemia (FH) in the US and Europe?
  • What are the Familial Hypercholesterolemia (FH) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Familial Hypercholesterolemia (FH)?
  • How many therapies are developed by each company for the treatment of Familial Hypercholesterolemia (FH)?
  • How many emerging therapies are in the mid-stage and late stage of development for the treatment of Familial Hypercholesterolemia (FH)?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Familial Hypercholesterolemia (FH) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Familial Hypercholesterolemia (FH) and their status?
  • What are the key designations that have been granted for the emerging therapies for Familial Hypercholesterolemia (FH)?
  • What are the 7MM historical and forecasted market of Familial Hypercholesterolemia (FH)?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Familial Hypercholesterolemia (FH).
  • To understand the future market competition in the asprgillosis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Familial Hypercholesterolemia (FH) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for Familial Hypercholesterolemia (FH) market.
  • To understand the future market competition in the Familial Hypercholesterolemia (FH) market.

Table of Contents

1 Key Insights

2 Familial Hypercholesterolemia Market Overview at a Glance

  • 2.1 Market Share (%) Distribution of Familial Hypercholesterolemia in 2017
  • 2.2 Market Share (%) Distribution of Familial Hypercholesterolemia in 2030

3 Executive Summary

4 Disease Background and Overview: Familial Hypercholesterolemia (FH)

  • 4.1 Introduction
  • 4.2 Types of Familial Hypercholesterolemia
    • 4.2.1 Homozygous Familial Hypercholesterolemia (HoFH)
    • 4.2.2 Heterozygous Familial Hypercholesterolemia (HeFH)
  • 4.3 FH Causative Genes
    • 4.3.1 LDL Receptor
    • 4.3.2 Apo B-100
    • 4.3.3 PCSK9
    • 4.3.4 LDL Receptor Adapter Protein 1 (LDLRAP1)
  • 4.4 Symptoms
  • 4.5 Clinical Features of FH
    • 4.5.1 Hyper-LDL-Cholesterolemia
    • 4.5.2 Premature Coronary Artery Disease
    • 4.5.3 Tendon and Skin Xanthomas
    • 4.5.4 Corneal Arcus
    • 4.5.5 Other Risk Factors in FH
  • 4.6 Diagnosis
    • 4.6.1 Detection of FH through Genetic Screening
    • 4.6.2 Detection of FH through Cascade Screening
    • 4.6.3 Achilles tendon radiography
    • 4.6.4 Diagnosis of Pediatric FH
    • 4.6.5 Establishing the Diagnosis
  • 4.7 Differential diagnosis

5 Diagnostic guidelines for Familial Hypercholesterolemia by the American Heart Association (AHA)

6 Diagnostic guidelines for Familial Hypercholesterolemia by the National Institute for Health and Care Excellence (NICE)

7 Recognized Establishments

  • 7.1 United States
  • 7.2 Europe
  • 7.3 Japan

8 Epidemiology and Patient Population

  • 8.1 Key Findings
  • 8.2 7MM Prevalent Population of Familial Hypercholesterolemia
  • 8.3 7MM Diagnosed Prevalent Population of Familial Hypercholesterolemia

9 Country-wise Epidemiology of Familial Hypercholesterolemia (FH)

  • 9.1 United States
    • 9.1.1 Assumptions and Rationale
    • 9.1.2 Prevalence of Familial Hypercholesterolemia in the United States
    • 9.1.3 Diagnosed Prevalence of Familial Hypercholesterolemia in the United States
    • 9.1.4 Age-specific Distribution of Familial Hypercholesterolemia in the United States
    • 9.1.5 Mutation-specific Distribution of Familial Hypercholesterolemia in the United States
  • 9.2 EU5 Countries
  • 9.3 Germany
    • 9.3.1 Assumptions and Rationale
    • 9.3.2 Prevalence of Familial Hypercholesterolemia in Germany
    • 9.3.3 Diagnosed Prevalence of Familial Hypercholesterolemia in Germany
    • 9.3.4 Age-specific Distribution of Familial Hypercholesterolemia in Germany
    • 9.3.5 Mutation-specific Distribution of Familial Hypercholesterolemia in Germany
  • 9.4 France
    • 9.4.1 Assumptions and Rationale
    • 9.4.2 Prevalence of Familial Hypercholesterolemia in France
    • 9.4.3 Diagnosed Prevalence of Familial Hypercholesterolemia in France
    • 9.4.4 Age-specific Distribution of Familial Hypercholesterolemia in France
    • 9.4.5 Mutation-specific Distribution of Familial Hypercholesterolemia in France
  • 9.5 Italy
    • 9.5.1 Assumptions and Rationale
    • 9.5.2 Prevalence of Familial Hypercholesterolemia in Italy
    • 9.5.3 Diagnosed Prevalence of Familial Hypercholesterolemia in Italy
    • 9.5.4 Age-specific Distribution of Familial Hypercholesterolemia in Italy
    • 9.5.5 Mutation-specific Distribution of Familial Hypercholesterolemia in Italy
  • 9.6 Spain
    • 9.6.1 Assumptions and Rationale
    • 9.6.2 Prevalence of Familial Hypercholesterolemia in Spain
    • 9.6.3 Diagnosed Prevalence of Familial Hypercholesterolemia in Spain
    • 9.6.4 Age-specific Distribution of Familial Hypercholesterolemia in Spain
    • 9.6.5 Mutation-specific Distribution of Familial Hypercholesterolemia in Spain
  • 9.7 United Kingdom
    • 9.7.1 Assumptions and Rationale
    • 9.7.2 Prevalence of Familial Hypercholesterolemia in the United Kingdom
    • 9.7.3 Diagnosed Prevalence of Familial Hypercholesterolemia in the United Kingdom
    • 9.7.4 Age-specific Distribution of Familial Hypercholesterolemia in the United Kingdom
    • 9.7.5 Mutation-specific Distribution of Familial Hypercholesterolemia in the United Kingdom
  • 9.8 Japan
    • 9.8.1 Assumptions and Rationale
    • 9.8.2 Prevalence of Familial Hypercholesterolemia in Japan
    • 9.8.3 Diagnosed Prevalence of Familial Hypercholesterolemia in Japan
    • 9.8.4 Age-specific Distribution of Familial Hypercholesterolemia in Japan
    • 9.8.5 Mutation-specific Distribution of Familial Hypercholesterolemia in Japan

10 Treatment

  • 10.1 Lifestyle Modifications
  • 10.2 Pharmacologic Treatment
    • 10.2.1 Statins
    • 10.2.2 Cholesterol Absorption Inhibitors
    • 10.2.3 Bile Acid Sequestrants
    • 10.2.4 Juxtapid (Lomitapide)
    • 10.2.5 PCSK9 Inhibitors
  • 10.3 Lipoprotein Apheresis
  • 10.4 Liver Transplantation

11 Treatment guidelines for Familial Hypercholesterolemia by the American Heart Association (AHA)

12 Treatment guidelines by the National Institute for Health and Care Excellence (NICE)

  • 12.1 Management of FH

13 Treatment guidelines for Familial Hypercholestrolemia by the Japan Atherosclerosis Society and the Asian Pacific Society of Atherosclerosis and Vascular Diseases

14 Unmet Needs

15 Marketed Drugs

  • 15.1 Key Competitiors
  • 15.2 Praluent (alirocumab): Sanofi/ Regeneron Pharmaceuticals
    • 15.2.1 Drug Description
    • 15.2.2 Regulatory Milestones
    • 15.2.3 Other Development Activities
    • 15.2.4 Current Pipeline Activity
    • 15.2.5 Safety and Efficacy
    • 15.2.6 Product Profile
  • 15.3 Repatha (evolocumab): Amgen
    • 15.3.1 Drug Description
    • 15.3.2 Regulatory Milestones
    • 15.3.3 Other Development Activities
    • 15.3.4 Current Pipeline Activity
    • 15.3.5 Safety and Efficacy
    • 15.3.6 Product Profile
  • 15.4 Nustendi/ Nexlizet (bempedoic acid/ ezetimibe): Esperion Therapeutics
    • 15.4.1 Drug Description
    • 15.4.2 Regulatory Milestones
    • 15.4.3 Other Development Activities
    • 15.4.4 Safety and Efficacy
    • 15.4.5 Product Profile
  • 15.5 Juxtapid (Lomitapide): Aegerion Pharmaceutical
    • 15.5.1 Drug Description
    • 15.5.2 Regulatory Milestones
    • 15.5.3 Other Development Activities
    • 15.5.4 Current Pipeline Activity
    • 15.5.5 Safety and Efficacy
    • 15.5.6 Product Profile
  • 15.6 Nexletol (bempedoic acid/ Nilemdo): Esperion Therapeutics
    • 15.6.1 Drug Description
    • 15.6.2 Regulatory Milestones
    • 15.6.3 Other Developmental Activities
    • 15.6.4 Safety and Efficacy
    • 15.6.5 Product Profile

16 Emerging Drugs

  • 16.1 Key Competitors
  • 16.2 Evinacumab (REGN1500): Regeneron Pharmaceuticals
    • 16.2.1 Drug Description
    • 16.2.2 Other Development Activities
    • 16.2.3 Clinical Development
    • 16.2.4 Safety and Efficacy
    • 16.2.5 Product Profile
  • 16.3 Inclisiran (ALN-PCSSC): Novartis
    • 16.3.1 Drug Description
    • 16.3.2 Other Development Activities
    • 16.3.3 Clinical Development
    • 16.3.4 Clinical Trials Information
    • 16.3.5 Safety and Efficacy
    • 16.3.6 Product Profile
  • 16.4 LIB003: LIB Therapeutics
    • 16.4.1 Drug Description
    • 16.4.2 Clinical Development
    • 16.4.3 Safety and Efficacy
    • 16.4.4 Product Profile
  • 16.5 Gemcabene: NeuroBo Pharmaceuticals
    • 16.5.1 Product Description
    • 16.5.2 Other Developmental Activities
    • 16.5.3 Clinical Development
    • 16.5.4 Safety and Efficacy
    • 16.5.5 Product Profile
  • 16.6 ARO-ANG3: Arrowhead Pharmaceuticals
    • 16.6.1 Product Description
    • 16.6.2 Other Developmental Activities
    • 16.6.3 Clinical Development
    • 16.6.4 Safety and Efficacy
    • 16.6.5 Product Profile

17 Familial Hypercholesterolemia (FH): Seven Major Market Analysis

  • 17.1 Key Findings
  • 17.2 Market Size of Familial Hypercholesterolemia (FH) in the 7MM
  • 17.3 7MM Market Outlook
  • 17.4 United States Market Size
    • 17.4.1 Total Market size of Familial Hypercholesterolemia
    • 17.4.2 Market Size by Current Therapies
    • 17.4.3 Market Size by Emerging Therapies
  • 17.5 Germany Market Size
    • 17.5.1 Total Market size of Familial Hypercholesterolemia
    • 17.5.2 Market Size by Current Therapies
    • 17.5.3 Market Size by Emerging Therapies
  • 17.6 France Market Size
    • 17.6.1 Total Market size of Familial Hypercholesterolemia
    • 17.6.2 Market Size by Current Therapies
    • 17.6.3 Market Size by Emerging Therapies
  • 17.7 Italy Market Size
    • 17.7.1 Total Market size of Familial Hypercholesterolemia
    • 17.7.2 Market Size by Current Therapies
    • 17.7.3 Market Size by Emerging Therapies
  • 17.8 Spain Market Size
    • 17.8.1 Total Market size of Familial Hypercholesterolemia
    • 17.8.2 Market Size by Current Therapies
    • 17.8.3 Market Size by Emerging Therapies
  • 17.9 United Kingdom Market Size
    • 17.9.1 Total Market size of Familial Hypercholesterolemia
    • 17.9.2 Market Size by Current Therapies
    • 17.9.3 Market Size by Emerging Therapies
  • 17.1 Japan market Size
    • 17.10.1 Total Market size of Familial Hypercholesterolemia
    • 17.10.2 Market Size by Current Therapies
    • 17.10.3 Market Size by Emerging Therapies

18 Case Reports

19 Market Drivers

20 Market Barriers

21 Market Access and Reimbursement

22 SWOT Analysis

23 Appendix

  • 23.1 Bibliography

24 Report Methodology

25 DelveInsight Capabilities

26 Disclaimer

27 About DelveInsight

List of Tables

  • Table 1: Summary of FH, Market, Epidemiology and Key Events (2017-2030)
  • Table 2: Diagnostic criteria for FH in Adults (15 years of age or older)
  • Table 3: Molecular Genetic Testing Used in Familial Hypercholesterolemia (FH)
  • Table 4: Pediatric FH diagnostic criteria
  • Table 5: Simon Broome Diagnostic Criteria for FH
  • Table 6: Make Early Diagnosis to Prevent Early Deaths (MEDPED) diagnostic criteria for HeFH
  • Table 7: The Dutch Lipid Clinics Network Criteria Score (DLCNS)
  • Table 8: Prevalent Population of FH in the 7MM (2017-2030)
  • Table 9: Diagnosed Prevalent Population of FH in the 7MM (2017-2030)
  • Table 10: Prevalence of FH in the US (2017-2030)
  • Table 11: Diagnosed Prevalence of FH in the US (2017-2030)
  • Table 12: Age-specific Distribution of FH in the US (2017-2030)
  • Table 13: Mutation-specific Distribution of FH in the US (2017-2030)
  • Table 14: Prevalence of FH in Germany (2017-2030)
  • Table 15: Diagnosed Prevalence of FH in Germany (2017-2030)
  • Table 16: Age-specific Distribution of FH in Germany (2017-2030)
  • Table 17: Mutation-specific Distribution of FH in Germany (2017-2030)
  • Table 18: Prevalence of FH in France (2017-2030)
  • Table 19: Diagnosed Prevalence of FH in France (2017-2030)
  • Table 20: Age-specific Distribution of FH in France (2017-2030)
  • Table 21: Mutation-specific Distribution of FH in France (2017-2030)
  • Table 22: Prevalence of FH in Italy (2017-2030)
  • Table 23: Diagnosed Prevalence of FH in Italy (2017-2030)
  • Table 24: Age-specific Distribution of FH in Italy (2017-2030)
  • Table 25: Mutation-specific Distribution of FH in Italy (2017-2030)
  • Table 26: Prevalence of FH in Spain (2017-2030)
  • Table 27: Diagnosed Prevalence of FH in Spain (2017-2030)
  • Table 28: Age-specific Distribution of FH in Spain (2017-2030)
  • Table 29: Mutation-specific Distribution of FH in Spain (2017-2030)
  • Table 30: Prevalence of FH in the UK (2017-2030)
  • Table 31: Diagnosed Prevalence of FH in the UK (2017-2030)
  • Table 32: Age-specific Distribution of FH in the UK (2017-2030)
  • Table 33: Mutation-specific Distribution of FH in the UK (2017-2030)
  • Table 34: Prevalence of FH in Japan (2017-2030)
  • Table 35: Diagnosed Prevalence of FH in Japan (2017-2030)
  • Table 36: Age-specific Distribution of FH in Japan (2017-2030)
  • Table 37: Mutation-specific Distribution of FH in Japan (2017-2030)
  • Table 38: Comparison of Marketed Drugs
  • Table 39: Praluent, Clinical Trial Description, 2020
  • Table 40: Repatha (Evolocumab/AMG 145), Clinical Trial Description, 2020
  • Table 41: Juxtapid (Lomitapide), Clinical Trial Description, 2020
  • Table 42: Comparison of emerging drugs under development
  • Table 43: Evinacumab (REGN1500), Clinical Trial Description;2020
  • Table 44: Inclisiran, Clinical Trial Description, 2020
  • Table 45: LIB003, Clinical Trial Description, 2020
  • Table 46: Gemcabene, Clinical Trial Description, 2020
  • Table 47: ARO-ANG3, Clinical Trial Description
  • Table 48: Seven Major Market Size of FH, in USD Million (2017-2030)
  • Table 49: Launch dates of potential emerging drugs
  • Table 50: Total Market Size of FH in the United States, in USD Million (2017-2030)
  • Table 51: Market size of FH by current therapies in the United States, in USD Million (2017-2030)
  • Table 52: Market size of FH by emerging therapies in the United States, in USD Million (2017-2030)
  • Table 53: Total Market Size of FH in Germany, in USD Million (2017-2030)
  • Table 54: Market size of FH by current therapies in Germany, in USD Million (2017-2030)
  • Table 55: Market size of FH by emerging therapies in Germany, in USD Million (2017-2030)
  • Table 56: Total Market Size of FH in France, in USD Million (2017-2030)
  • Table 57: Market size of FH by current therapies in France, in USD Million (2017-2030)
  • Table 58: Market size of FH by emerging therapies in France, in USD Million (2017-2030)
  • Table 59: Total Market Size of FH in Italy, in USD Million (2017-2030)
  • Table 60: Market size of FH by current therapies in Italy, in USD Million (2017-2030)
  • Table 61: Market size of FH by emerging therapies in Italy, in USD Million (2017-2030)
  • Table 62: Total Market Size of FH in Spain, in USD Million (2017-2030)
  • Table 63: Market size of FH by current therapies in Spain, in USD Million (2017-2030)
  • Table 64: Market size of FH by emerging therapies in Spain, in USD Million (2017-2030)
  • Table 65: Total Market Size of FH in the United Kingdom, in USD Million (2017-2030)
  • Table 66: Market size of FH by current therapies in the United Kingdom, in USD Million (2017-2030)
  • Table 67: Market size of FH by emerging therapies in the United Kingdom, in USD Million (2017-2030)
  • Table 68: Total Market Size of FH in Japan, in USD Million (2017-2030)
  • Table 69: Market size of FH by current therapies in Japan, in USD Million (2017-2030)
  • Table 70: Market size of FH by emerging therapies in Japan, in USD Million (2017-2030)
  • Table 71: Parameters for Government Funding for FH Care, Research, Regulation of Payer Structure, and Support for Education

List of Figures

  • Figure 1: A typical diagram showing FH artery of FH patient
  • Figure 2: Combination of genetic mutation showing a clinical phenotype of FH homozygote.
  • Figure 3: Corneal arcus in FH patients
  • Figure 4: Diagnostic considerations by the American Heart Association
  • Figure 5: Prevalent Population of FH in the 7MM (2017-2030)
  • Figure 6: Diagnosed Prevalent Population of FH in the 7MM (2017-2030)
  • Figure 7: Prevalence of FH in the US (2017-2030)
  • Figure 8: Diagnosed Prevalence of FH in the US (2017-2030)
  • Figure 9: Age-specific Distribution of FH in the US (2017-2030)
  • Figure 10: Mutation-specific Distribution of FH in the US (2017-2030)
  • Figure 11: Prevalence of FH in Germany (2017-2030)
  • Figure 12: Diagnosed Prevalence of FH in Germany (2017-2030)
  • Figure 13: Age-specific Distribution of FH in Germany (2017-2030)
  • Figure 14: Mutation-specific Distribution of FH in Germany (2017-2030)
  • Figure 15: Prevalence of FH in France (2017-2030)
  • Figure 16: Diagnosed Prevalence of FH in France (2017-2030)
  • Figure 17: Age-specific Distribution of FH in France (2017-2030)
  • Figure 18: Mutation-specific Distribution of FH in France (2017-2030)
  • Figure 19: Prevalence of FH in Italy (2017-2030)
  • Figure 20: Diagnosed Prevalence of FH in Italy (2017-2030)
  • Figure 21: Age-specific Distribution of FH in Italy (2017-2030)
  • Figure 22: Mutation-specific Distribution of FH in Italy (2017-2030)
  • Figure 23: Prevalence of FH in Spain (2017-2030)
  • Figure 24: Diagnosed Prevalence of FH in Spain (2017-2030)
  • Figure 25: Age-specific Distribution of FH in Spain (2017-2030)
  • Figure 26: Mutation-specific Distribution of FH in Spain (2017-2030)
  • Figure 27: Prevalence of FH in the UK (2017-2030)
  • Figure 28: Diagnosed Prevalence of FH in the UK (2017-2030)
  • Figure 29: Age-specific Distribution of FH in the UK (2017-2030)
  • Figure 30: Mutation-specific Distribution of FH in the UK (2017-2030)
  • Figure 31: Prevalence of FH in Japan (2017-2030)
  • Figure 32: Diagnosed Prevalence of FH in Japan (2017-2030)
  • Figure 33: Age-specific Distribution of FH in Japan (2017-2030)
  • Figure 34: Mutation-specific Distribution of FH in Japan (2017-2030)
  • Figure 35: Treatment algorithm for FH patients
  • Figure 36: Treatment algorithm for adult (15 years or over) heterozygous FH patients
  • Figure 37: Treatment algorithm for adult (15 years or over) homozygous FH patients
  • Figure 38: Seven Major Market Size of FH, in USD Million (2017-2030)
  • Figure 39: Total Market Size of FH in the United States, in USD Millions (2017-2030)
  • Figure 40: Market size of FH by current therapies in the United States, in USD Million (2017-2030)
  • Figure 41: Market size of FH by emerging therapies in the United States, in USD Million (2017-2030)
  • Figure 42: Total Market Size of FH in Germany, in USD Millions (2017-2030)
  • Figure 43: Market size of FH by current therapies in Germany, in USD Million (2017-2030)
  • Figure 44: Market size of FH by emerging therapies in Germany, in USD Million (2017-2030)
  • Figure 45: Total Market Size of FH in France, in USD Millions (2017-2030)
  • Figure 46: Market size of FH by current therapies in France, in USD Million (2017-2030)
  • Figure 47: Market size of FH by emerging therapies in France, in USD Million (2017-2030)
  • Figure 48: Total Market Size of FH in Italy, in USD Millions (2017-2030)
  • Figure 49: Market size of FH by current therapies in Italy, in USD Million (2017-2030)
  • Figure 50: Market size of FH by emerging therapies in Italy, in USD Million (2017-2030)
  • Figure 51: Total Market Size of FH in Spain, in USD Millions (2017-2030)
  • Figure 52: Market size of FH by current therapies in Spain, in USD Million (2017-2030)
  • Figure 53: Market size of FH by emerging therapies in Spain, in USD Million (2017-2030)
  • Figure 54: Total Market Size of FH in the UK, in USD Millions (2017-2030)
  • Figure 55: Market size of FH by current therapies in the UK, in USD Million (2017-2030)
  • Figure 56: Market size of FH by emerging therapies in the UK, in USD Million (2017-2030)
  • Figure 57: Total Market Size of FH in Japan, in USD Million (2017-2030)
  • Figure 58: Market size of FH by current therapies in Japan, in USD Million (2017-2030)
  • Figure 59: Market size of FH by emerging therapies in Japan, in USD Million (2017-2030)
  • Figure 60: Market Drivers
  • Figure 61: Market Barriers
  • Figure 62: SWOT Analysis of Familial Hypercholesterolemia